| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/27/2023 | 2.45% | TD Cowen | $165 → $160 | Downgrades | Outperform → Market Perform |
| 11/01/2023 | 19.09% | RBC Capital | $183 → $186 | Maintains | Outperform |
| 09/21/2023 | 16.53% | RBC Capital | → $182 | Reiterates | Outperform → Outperform |
| 08/07/2023 | 24.86% | Seaport Global | → $195 | Initiates Coverage On | → Buy |
| 08/02/2023 | 16.53% | RBC Capital | $174 → $182 | Maintains | Outperform |
| 08/02/2023 | 11.41% | Morgan Stanley | $162 → $174 | Maintains | Overweight |
| 08/02/2023 | 6.29% | Mizuho | $161 → $166 | Maintains | Buy |
| 08/02/2023 | 18.45% | Wells Fargo | $180 → $185 | Maintains | Overweight |
| 08/02/2023 | 12.69% | Keybanc | $165 → $176 | Maintains | Overweight |
| 07/12/2023 | 3.73% | Morgan Stanley | $159 → $162 | Maintains | Overweight |
| 06/08/2023 | 15.25% | DA Davidson | $177 → $180 | Maintains | Buy |
| 05/04/2023 | 1.81% | Morgan Stanley | $155 → $159 | Maintains | Overweight |
| 05/03/2023 | 5.65% | RBC Capital | → $165 | Reiterates | → Outperform |
| 05/03/2023 | 3.09% | Mizuho | $153 → $161 | Maintains | Buy |
| 02/23/2023 | — | Wolfe Research | Downgrades | Outperform → Peer Perform | |
| 02/03/2023 | -0.76% | Morgan Stanley | $152 → $155 | Maintains | Overweight |
| 01/13/2023 | -2.04% | Mizuho | $145 → $153 | Maintains | Buy |
| 01/06/2023 | -2.68% | Morgan Stanley | $144 → $152 | Maintains | Overweight |
| 11/21/2022 | 5.65% | Keybanc | $145 → $165 | Maintains | Overweight |
| 11/02/2022 | -12.92% | RBC Capital | $135 → $136 | Maintains | Outperform |
| 11/02/2022 | -7.16% | Mizuho | $140 → $145 | Maintains | Buy |
| 11/02/2022 | -7.8% | Morgan Stanley | $137 → $144 | Maintains | Overweight |
| 10/24/2022 | 5.65% | Wells Fargo | $180 → $165 | Maintains | Overweight |
| 10/12/2022 | -12.28% | Morgan Stanley | $145 → $137 | Maintains | Overweight |
| 08/03/2022 | -10.36% | Mizuho | $135 → $140 | Maintains | Buy |
| 08/03/2022 | -7.16% | Morgan Stanley | $135 → $145 | Maintains | Overweight |
| 08/03/2022 | -13.56% | RBC Capital | $134 → $135 | Maintains | Outperform |
| 07/19/2022 | -0.76% | Loop Capital | $170 → $155 | Maintains | Buy |
| 07/18/2022 | -13.56% | Mizuho | $159 → $135 | Maintains | Buy |
| 07/11/2022 | -21.89% | B of A Securities | → $122 | Downgrades | Buy → Neutral |
| 05/31/2022 | -13.56% | Morgan Stanley | $144 → $135 | Maintains | Overweight |
| 05/04/2022 | -7.8% | Morgan Stanley | $158 → $144 | Maintains | Overweight |
| 05/04/2022 | -5.24% | RBC Capital | $146 → $148 | Maintains | Outperform |
| 05/04/2022 | -7.16% | Keybanc | $155 → $145 | Maintains | Overweight |
| 03/18/2022 | -0.76% | Keybanc | $160 → $155 | Maintains | Overweight |
| 01/14/2022 | 1.17% | Morgan Stanley | $159 → $158 | Maintains | Overweight |
| 12/17/2021 | 1.81% | Mizuho | → $159 | Initiates Coverage On | → Buy |
| 12/14/2021 | 6.29% | Wolfe Research | $162 → $166 | Upgrades | Peer Perform → Outperform |
| 11/03/2021 | 1.81% | Morgan Stanley | $154 → $159 | Maintains | Overweight |
| 11/03/2021 | 5.01% | RBC Capital | $160 → $164 | Maintains | Outperform |
| 10/07/2021 | -1.4% | Morgan Stanley | $156 → $154 | Maintains | Overweight |
| 08/04/2021 | -0.12% | Morgan Stanley | $151 → $156 | Maintains | Overweight |
| 08/04/2021 | 2.45% | Rosenblatt | $155 → $160 | Maintains | Buy |
| 08/04/2021 | 2.45% | Keybanc | $150 → $160 | Maintains | Overweight |
| 05/05/2021 | -3.32% | Morgan Stanley | $135 → $151 | Maintains | Overweight |
| 05/05/2021 | -3.96% | Keybanc | $141 → $150 | Maintains | Overweight |
| 04/20/2021 | 2.45% | Wells Fargo | $140 → $160 | Maintains | Overweight |
| 04/13/2021 | -9.72% | Keybanc | $140 → $141 | Maintains | Overweight |
| 04/12/2021 | -13.56% | Morgan Stanley | $133 → $135 | Maintains | Overweight |
| 04/01/2021 | -10.36% | Keybanc | $131 → $140 | Maintains | Overweight |
| 03/30/2021 | -9.08% | Rosenblatt | $140 → $142 | Maintains | Buy |
| 03/09/2021 | -16.12% | Keybanc | $130 → $131 | Maintains | Overweight |
| 02/05/2021 | -14.84% | Morgan Stanley | $131 → $133 | Maintains | Overweight |
| 11/24/2020 | -16.12% | Morgan Stanley | $117 → $131 | Maintains | Overweight |
| 11/23/2020 | -16.12% | Morgan Stanley | $117 → $131 | Maintains | Overweight |
| 11/13/2020 | -16.76% | Keybanc | $118 → $130 | Maintains | Overweight |
| 10/30/2020 | -25.09% | Morgan Stanley | $112 → $117 | Maintains | Overweight |
| 10/30/2020 | -18.04% | Rosenblatt | $125 → $128 | Maintains | Buy |
| 10/14/2020 | -24.45% | Keybanc | $112 → $118 | Maintains | Overweight |
| 10/13/2020 | -28.29% | Morgan Stanley | $105 → $112 | Maintains | Overweight |
| 08/07/2020 | -32.77% | Morgan Stanley | $98 → $105 | Maintains | Overweight |
| 08/05/2020 | -28.29% | Keybanc | $100 → $112 | Maintains | Overweight |
| 07/14/2020 | -37.25% | Morgan Stanley | $90 → $98 | Maintains | Overweight |
| 06/18/2020 | -33.41% | Rosenblatt | $92 → $104 | Maintains | Buy |
| 06/12/2020 | — | Oppenheimer | Downgrades | Outperform → Perform | |
| 05/26/2020 | — | B of A Securities | Upgrades | Neutral → Buy | |
| 05/06/2020 | -46.22% | Baird | $80 → $84 | Maintains | Neutral |
| 05/06/2020 | -42.37% | Morgan Stanley | $82 → $90 | Maintains | Overweight |
| 04/15/2020 | -47.5% | Morgan Stanley | $75 → $82 | Maintains | Overweight |
| 03/30/2020 | -35.97% | Keybanc | $110 → $100 | Maintains | Overweight |
| 03/17/2020 | -50.06% | Morgan Stanley | $107 → $78 | Maintains | Overweight |
| 03/16/2020 | -39.17% | Wells Fargo | $120 → $95 | Maintains | Overweight |
| 03/12/2020 | -39.17% | Cowen & Co. | $100 → $95 | Upgrades | Market Perform → Outperform |
| 02/07/2020 | -26.37% | Stephens & Co. | $113 → $115 | Maintains | Overweight |
| 02/06/2020 | -37.25% | Baird | $96 → $98 | Maintains | Neutral |
| 01/16/2020 | -38.53% | Baird | → $96 | Downgrades | Outperform → Neutral |
| 01/14/2020 | -31.49% | Morgan Stanley | $109 → $107 | Maintains | Overweight |
| 01/13/2020 | — | Cowen & Co. | Downgrades | Outperform → Market Perform | |
| 01/09/2020 | — | Wolfe Research | Downgrades | Outperform → Peer Perform | |
| 12/11/2019 | -30.21% | Morgan Stanley | $102 → $109 | Maintains | Overweight |
| 11/19/2019 | -19.96% | Gordon Haskett | → $125 | Initiates Coverage On | → Buy |
| 11/19/2019 | -29.57% | Keybanc | $100 → $110 | Maintains | Overweight |
| 11/07/2019 | -26.37% | Rosenblatt | → $115 | Initiates Coverage On | → Buy |
| 11/01/2019 | -34.69% | Morgan Stanley | $97 → $102 | Maintains | Overweight |
| 10/11/2019 | — | B of A Securities | Downgrades | Buy → Neutral | |
| 07/31/2019 | -37.89% | Morgan Stanley | $95 → $97 | Maintains | Overweight |
| 05/15/2019 | -35.97% | Berenberg | → $100 | Initiates Coverage On | → Buy |
| 05/02/2019 | -35.33% | BMO Capital | $99 → $101 | Maintains | Outperform |
| 05/02/2019 | -39.81% | Keybanc | $86 → $94 | Maintains | Overweight |
| 12/18/2018 | -45.58% | Morgan Stanley | $81 → $85 | Upgrades | Equal-Weight → Overweight |
What is the target price for AMETEK (AME)?
The latest price target for AMETEK (NYSE: AME) was reported by TD Cowen on November 27, 2023. The analyst firm set a price target for $160.00 expecting AME to rise to within 12 months (a possible 2.45% upside). 18 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for AMETEK (AME)?
The latest analyst rating for AMETEK (NYSE: AME) was provided by TD Cowen, and AMETEK downgraded their market perform rating.
When is the next analyst rating going to be posted or updated for AMETEK (AME)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of AMETEK, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for AMETEK was filed on November 27, 2023 so you should expect the next rating to be made available sometime around November 27, 2024.
Is the Analyst Rating AMETEK (AME) correct?
While ratings are subjective and will change, the latest AMETEK (AME) rating was a downgraded with a price target of $165.00 to $160.00. The current price AMETEK (AME) is trading at is $156.18, which is out of the analyst's predicted range.